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the major risk factors in carcinogenesis of head and neck can-
cer (HNSCC). However, during the past decade a causal asso-
ciation between infection with human papillomavirus (HPV)
and HNSCC has been established [1], and this ‘new’ aetiolog-
ical factor has changed the conventional understanding of
HNSCC because of the extensive influence of the virus on
the epidemiology, clinical presentation and treatment out-
come for patients with HNSCC.
Association with HPV is predominantly a matter of con-
cern in tumours of the oropharynx, especially in tonsillar can-
cer [2,3], and a dramatic increase in the incidence of
oropharyngeal cancer (OPC) has been reported in several Wes-
tern countries over the past 30 years [4–8]. Based on the obser-
vations that, simultaneously, there has been an increase in
the frequency of HPV-positivity among OPCs [4,9], infection
with HPV seems to be the dominant cause of this develop-
ment. Moreover, in the same time period a decrease in tobac-
co-smoking seems to be responsible for a reduction in the
incidence of HNSCC outside the oropharynx [6], at least in
Western countries. The natural history of oral HPV infection
remains to be fully elucidated, and although the exact mech-
anism is not known, oral–genital contact is assumed to be the
primary mode by which HPV is transmitted to the oral muco-
sa, and several case–control studies have shown an associa-
tion between HPV-related HNSCC and sexual behaviour
(reviewed by Gillison et al. [3]). The optimal method for
detecting HPV in tumours is controversial, and both in-situ
hybridisation and the polymerase chain reaction (PCR) are
commonly used; p16-immunohistochemistry has gained
broad acceptance as a surrogate marker and is also widely
used in the clinical setting [10,11].
HPV-related HNSCC constitutes a clinically distinct sub-
group of cancers in terms of molecular biology, patient char-
acteristics and sensitivity to treatment, and this on the
whole differentiates it markedly from HPV-negative tu-
mours. The molecular profile of HPV-related HNSCC is dis-
tinct, with P53 degradation, retinoblastoma RB pathwayinactivation and p16 up-regulation. By contrast, HPV-negative
tumours are characterised by TP53 mutation and down-
regulation of p16 [12,13]. Patients with HPV-related HNSCC
tend to be younger, have less comorbidity and a better per-
formance status [14–16], and are less declined to be abusers
of tobacco and alcohol [6,15] compared with HPV-negative
patients.
Tumour HPV status has a major impact on outcome for pa-
tients with HNSCC, and compared with HPV-negative pa-
tients, tumour-control and survival are highly significantly
better for patients with HPV-positive tumours. This has been
shown repeatedly in several clinical trials and with the use of
a variety of different treatment schedules [17–22] and is be-
lieved to be caused in part by a higher sensitivity to radiother-
apy of HPV-positive tumours, presumably because of the
distinct molecular profile [23], combined with a better general
health status in this group of patients. Smoking negatively af-
fects survival in HNSCC, and the accumulated lifetime num-
ber of pack years independently impacts prognosis for both
HPV-positive and -negative tumours [21,24]; implementation
of smoking history in the risk stratification of HNSCC is under
consideration.
As a consequence of this profound impact of HPV in
HNSCC, this ‘new’ type of cancer has attracted a lot of
attention, and separate therapeutic treatment strategies
based on tumour HPV status are in the pipeline. In light
of the enhanced sensitivity to treatment of HPV-related
HNSCC, de-intensification of present treatment strategies
in order to avoid excessive toxicity has been proposed for
selected patients with minimal risk of distant metastasis
[25]. On the other hand, patients with HPV-negative tumours
have a very poor prognosis, and efforts should be made to
improve treatment efficacy and compliance in this group
of patients.
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